Genetics company 23andMe is expected to be purchased by Regeneron Pharmaceuticals, according to announcements shared by both companies Both companies vowed that Regeneron is committed to comply with 23andMe's privacy policies,

Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, promising to honor existing privacy protections and continue consumer services with no changes.